Policy & Regulation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
![](/-/media/editorial/medtech-insight/00_regular-column-images/mti2301_newswerewatching_1200.png?rev=688714c023c14838b737c7a06cd71521&w=350&hash=96B7B2D80A4AD95988467585BE50FE74)
News We’re Watching: Edwards Scoops Up Cardio Firms, BD And Quest Partner, Admera Settles Kickback Case
This week, Edwards announced that it has purchased JenaValve and Endotronix; a New Jersey lab has agreed to pay the government $5m for violating anti-kickback law; eCential Robotics’ spine platform made its debut for human use; and more.
![](/-/media/editorial/medtech-insight/2024/07/mt2407_dhcoe-lifecycle.png?rev=481c6ef08706409e81a7ddb2c1b072d1&w=350&hash=4FDAA56EFE17D16EC4E7738D3F6AB092)
DHCoE AI Lifecycle Management Plan To Serve As ‘Playbook’ For Standards
A new AI lifecycle management framework from the US FDA’s Digital Health Center of Excellence introduces considerations for the seven steps of the AI lifecycle.
![](/-/media/editorial/medtech-insight/2024/07/mti-abbottfreestyle-1200.jpg?rev=7bdc0e89183d4125a9aeea54df737252&w=350&hash=5F2ABCBC58BBC9BC38C708FDFE329FD0)
Abbott Issues Correction On Faulty Glucose Monitors
Abbott has issued an urgent voluntary medical device correction for a small number of FreeStyle Libre 3 sensors distributed in the US during May. The sensors could give inaccurate readings, the company explained.
![](/-/media/editorial/products/b/biolinq_sensor_1200.png?rev=a03e95a840684e23a48ad7c43eb26de5&w=350&hash=BC7C26E36DDD0C91AD7C316CCD0E439A)
Biolinq Aims To Transform Diabetic Glucose Monitoring With Needle-Free Patch
Biolinq’s CEO Rich Yang spoke to Medtech Insight about the company’s wearable patch in development, which uses tiny microsensors to measure, for now, glucose, with ample runway for additional indications down the line. If approved by the US FDA, the device would become the first of its kind to monitor glucose levels in diabetes patients not using insulin.
![](/-/media/editorial/medtech-insight/2018/12/mt1812_innovativesolution_322900712_1200x675.jpg?rev=723038717bc44e5f98d0660e70888327&w=350&hash=218B619ECE046D30EB80856C6145E464)
How The EU Must Address Regulatory Hurdles Deterring Medtech Investors
In the EU, developers struggle to tell potential investors how many trials a device might require, the potential duration or associated costs. Tom Melvin explains how to tackle these issues in a third piece* based on a recent interview.
![](/-/media/editorial/medtech-insight/2024/07/mti-faqs-1200.jpg?rev=dc38e4ef8f4c4e51a4153d7868100a19&w=350&hash=1F84CABBAFB913EBCCDC42746C31EC10)
FDA Publishes FAQs On Final Rule Establishing Oversight Of LDTs
The US FDA has created a web page with answers to common questions concerning the agency’s final rule on regulating laboratory developed tests as medical devices.
![](/-/media/editorial/stock-images/business/manbinocularslaptop_731756935_1200x675.jpg?rev=5a06fd3bd8ff4917994a233a46931bae&w=350&hash=5AA2B1FDF86AF0E5359DA0E3128E1E5B)
EU Must Widen Debate Around Medtech Regulations Beyond Liese’s Proposal
The EU needs to conduct a deeper, more decisive analysis of its medtech regulatory problems before it decides how to adopt elements of MEP Peter Liese’s proposed amending regulation, regulatory expert Tom Melvin told Medtech Insight.
![](/-/media/editorial/medtech-insight/2024/07/mti-warningletter-1200.jpg?rev=12aa8432c6ac414091f1ea69561b8cd9&w=350&hash=AA5FC4BA23A5FD5E3DBA56F9B98C0C33)
Inspections Of Chinese Syringe Manufacturer Prompts Additional Warnings
The US FDA has issued two new warning letters to Chinese syringe makers Jiangsu Shenli and Jiangsu Caina following inspections of their facilities. The letters are the latest in what has been an ongoing investigation into these devices.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.